S.C. Ropharma S.A.

BVB:RPH Stock Report

Market Cap: RON 87.9m

S.C. Ropharma Past Earnings Performance

Past criteria checks 1/6

S.C. Ropharma's earnings have been declining at an average annual rate of -2.9%, while the Consumer Retailing industry saw earnings growing at 5.6% annually. Revenues have been growing at an average rate of 9.7% per year. S.C. Ropharma's return on equity is 2%, and it has net margins of 0%.

Key information

-2.9%

Earnings growth rate

-3.0%

EPS growth rate

Consumer Retailing Industry Growth12.4%
Revenue growth rate9.7%
Return on equity2.0%
Net Margin0.003%
Last Earnings Update30 Jun 2024

Recent past performance updates

We Wouldn't Rely On S.C. Ropharma's (BVB:RPH) Statutory Earnings As A Guide

Nov 24
We Wouldn't Rely On S.C. Ropharma's (BVB:RPH) Statutory Earnings As A Guide

Recent updates

S.C. Ropharma (BVB:RPH) Is Experiencing Growth In Returns On Capital

Dec 06
S.C. Ropharma (BVB:RPH) Is Experiencing Growth In Returns On Capital

Here's What's Concerning About S.C. Ropharma's (BVB:RPH) Returns On Capital

Dec 09
Here's What's Concerning About S.C. Ropharma's (BVB:RPH) Returns On Capital

S.C. Ropharma (BVB:RPH) Is Reinvesting At Lower Rates Of Return

Sep 23
S.C. Ropharma (BVB:RPH) Is Reinvesting At Lower Rates Of Return

Is S.C. Ropharma (BVB:RPH) Using Too Much Debt?

Jun 01
Is S.C. Ropharma (BVB:RPH) Using Too Much Debt?

Some Investors May Be Worried About S.C. Ropharma's (BVB:RPH) Returns On Capital

Mar 16
Some Investors May Be Worried About S.C. Ropharma's (BVB:RPH) Returns On Capital

S.C. Ropharma (BVB:RPH) Takes On Some Risk With Its Use Of Debt

May 15
S.C. Ropharma (BVB:RPH) Takes On Some Risk With Its Use Of Debt

S.C. Ropharma (BVB:RPH) Might Be Having Difficulty Using Its Capital Effectively

Mar 26
S.C. Ropharma (BVB:RPH) Might Be Having Difficulty Using Its Capital Effectively

Should You Be Impressed By S.C. Ropharma's (BVB:RPH) Returns on Capital?

Dec 23
Should You Be Impressed By S.C. Ropharma's (BVB:RPH) Returns on Capital?

We Wouldn't Rely On S.C. Ropharma's (BVB:RPH) Statutory Earnings As A Guide

Nov 24
We Wouldn't Rely On S.C. Ropharma's (BVB:RPH) Statutory Earnings As A Guide

Revenue & Expenses Breakdown

How S.C. Ropharma makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BVB:RPH Revenue, expenses and earnings (RON Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 241,18701980
31 Mar 241,15441910
31 Dec 231,12081850
30 Sep 231,09991780
30 Jun 231,078101710
31 Mar 231,040101640
31 Dec 221,00291570
30 Sep 22976101530
30 Jun 22951121490
31 Mar 22919111460
31 Dec 21888111430
30 Sep 21857101380
30 Jun 2182691340
31 Mar 2181681290
31 Dec 2080671250
30 Sep 2078761220
30 Jun 2076951180
31 Mar 2077661150
31 Dec 1978481120
30 Sep 1977481140
30 Jun 1976491150
31 Mar 19700111110
31 Dec 18636121060
30 Sep 18596121000
30 Jun 1855512940
31 Mar 1854512940
31 Dec 1753512940
30 Sep 1753212890
30 Jun 1753013850
31 Mar 1751912820
31 Dec 1650710790
31 Dec 154719620
31 Dec 144327550
30 Sep 144128360
30 Jun 144108370
31 Mar 144117370
31 Dec 134227530

Quality Earnings: RPH has high quality earnings.

Growing Profit Margin: RPH's current net profit margins (0%) are lower than last year (0.9%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: RPH's earnings have declined by 2.9% per year over the past 5 years.

Accelerating Growth: RPH's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: RPH had negative earnings growth (-99.6%) over the past year, making it difficult to compare to the Consumer Retailing industry average (-8.4%).

Return on Equity

High ROE: RPH's Return on Equity (2%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 11:57
End of Day Share Price 2024/12/23 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

S.C. Ropharma S.A. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Roxana DascaluSSIF IEBA Trust SA